Clinical trial WO29522
A Phase III, MULTICENTER, RANDOMIZED, placebo-controlled Study OF MPDL3280A (Anti-PD-L1 Antibody) IN COMBINATION WITH NAB-PACLITAXEL COMPARED with placebo with NAB-PACLITAXEL for PATIENTS WITH previously UNtreated metastatic TRIPLE-NEGATIVE BREAST CANCER
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Roche |
EudraCT Identifier | 2014-005490-37 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02425891 |
Inclusion criteria | Triple negative. Metastatic. 1st Line |
Last update |